Modality
Degrader
MOA
HER2
Target
BCL-2
Pathway
Ferroptosis
IgAN
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Jun 2030
Phase 1Current
NCT03691393
1,999 pts·IgAN
2018-02→2030-06·Terminated
1,999 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-034.2y awayPh2 Data· IgAN
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Termina…
Catalysts
Ph2 Data
2030-06-03 · 4.2y away
IgAN
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03691393 | Phase 1/2 | IgAN | Terminated | 1999 | DAS28 |
Competitors (10)